Although multiple studies have confirmed that trastuzumab is beneficial for the treatment of HER2 positive breast cancer [3,7,9,10,11], the clinical efficacy is dependent on the level of HER2 expression [12]. Here, ERBB2 is linked to breast carcinoma.